PTI 110Alternative Names: AA-amyloidosis therapeutic - ProteoTech; PTI-110; Systebryl
Latest Information Update: 14 Jan 2015
At a glance
- Originator ProteoTech
- Class Small molecules
- Mechanism of Action Amyloid fibril protein AL inhibitors; Amyloid inhibitors; Serum amyloid A protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase 0 Amyloidosis